title: A limited comparison of apraclonidine's dose response in subjects with normal or increased intraocular pressure.
abstract: We performed a multicentered, placebo-controlled, randomized, crossover study comparing the efficacy of 0.5% and 1.0% apraclonidine hydrochloride in 15 normal volunteers and 17 subjects with increased intraocular pressure. Apraclonidine 1% produced a maximum 30.4% +/- 14.0% (4.7 +/- 2.4 mm Hg) decrease in mean intraocular pressure in normal eyes and a 31.3% +/- 16.5% (7.6 +/- 4.2 mm Hg) decrease in eyes with increased pressure. Apraclonidine 0.5% produced a maximum 25.8% +/- 9.7% (4.0 +/- 1.7 mm Hg) decrease in mean intraocular pressure in normal eyes and a 27.4% +/- 16.0% (6.8 +/- 4.5 mm Hg) decrease in eyes with increased pressure. There was no statistically significant difference in mean percent intraocular pressure lowering effect between the 0.5% and 1.0% apraclonidine concentrations. Most subjects treated with apraclonidine had a greater than or equal to 20% reduction in intraocular pressure from baseline. Twelve hours after instillation of apraclonidine, nine of the normal volunteers had an intraocular pressure of 10 mm Hg or less. Apraclonidine produced the same percent intraocular pressure decrease regardless of the initial level of intraocular pressure.
authors.affiliation: Glaucoma Service, Sinai Hospital, Baltimore, MD.
authors.forename: D A
authors.initials: DA
authors.lastname: Abrams
authors.forename: A L
authors.initials: AL
authors.lastname: Robin
authors.forename: A S
authors.initials: AS
authors.lastname: Crandall
authors.forename: D R
authors.initials: DR
authors.lastname: Caldwell
authors.forename: D B
authors.initials: DB
authors.lastname: Schnitzer
authors.forename: I P
authors.initials: IP
authors.lastname: Pollack
authors.forename: J E
authors.initials: JE
authors.lastname: Rader
authors.forename: T A
authors.initials: TA
authors.lastname: Reaves
mesh_terms: D000328:Adult; D000368:Aged; D002940:Circadian Rhythm; D002986:Clinical Trials as Topic; D003000:Clonidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009798:Ocular Hypertension / Q000188:drug therapy*; D010919:Placebos; D011897:Random Allocation; D013997:Time Factors
chemical_list: D010919:Placebos; C016986:apraclonidine; D003000:Clonidine